Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Summary

RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.

PURPOSE: This phase II trial is studying how well peripheral stem cell transplant works in treating patients with high-risk leukemia.

Conditions

• Chronic Myeloproliferative Disorders
• Leukemia
• Myelodysplastic/Myeloproliferative Diseases

Interventions

DRUG

cyclophosphamide

DRUG

cyclosporine

DRUG

fludarabine phosphate

DRUG

methylprednisolone

DRUG

therapeutic allogeneic lymphocytes

DRUG

thiotepa

PROCEDURE

allogeneic bone marrow transplantation

PROCEDURE

biological therapy

PROCEDURE

bone marrow ablation with stem cell support

PROCEDURE

bone marrow transplantation

PROCEDURE

chemotherapy

PROCEDURE

leukocyte therapy

PROCEDURE

non-specific immune-modulator therapy

PROCEDURE

peripheral blood lymphocyte therapy

PROCEDURE

peripheral blood stem cell transplantation

PROCEDURE

radiation therapy

Sponsors & Collaborators

• National Heart, Lung, and Blood Institute (NHLBI)

  lead NIH

Principal Investigators

• Bipin N. Savani, MD · National Heart, Lung, and Blood Institute (NHLBI)

Study Design

Purpose

TREATMENT

Masking

NONE

Eligibility

Min Age

10 Years

Max Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Completion

2007-01-31

Countries

• United States

Study Locations